Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Receives Average Recommendation of “Moderate Buy” from Brokerages

Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company.

A number of equities analysts have commented on BIOVF shares. Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Pareto Securities downgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st.

Get Swedish Orphan Biovitrum alerts:

Get Our Latest Stock Analysis on Swedish Orphan Biovitrum

Swedish Orphan Biovitrum Price Performance

OTCMKTS BIOVF opened at $42.80 on Tuesday. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 0.20. The company has a market cap of $15.24 billion, a price-to-earnings ratio of 95.11 and a beta of 0.47. The company has a 50 day moving average of $47.31 and a 200-day moving average of $46.27. Swedish Orphan Biovitrum has a 1-year low of $34.88 and a 1-year high of $49.03.

About Swedish Orphan Biovitrum

(Get Free Report)

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing treatments for rare diseases. Its activities center on conditions in hematology, immunology and specialty care, where patients often have limited treatment options.

Sobi’s portfolio includes therapies for hemophilia and other bleeding disorders, immune-mediated diseases, and rare inflammatory or hematologic conditions. Its products include Elocta and Alprolix for hemophilia, Doptelet for certain platelet disorders, Gamifant for primary hemophagocytic lymphohistiocytosis, and Aspaveli for paroxysmal nocturnal hemoglobinuria.

See Also

• Five stocks we like better than Swedish Orphan Biovitrum
• Want Private-Market Access to Kalshi and Polymarket? Try This ETF
• Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
• PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
• Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push

Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.